Image (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 01)
Dapagliflozin Tablet
Product Images NDC 70748-105
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Dapagliflozin (NDC 70748-105). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 02)
This is a list of data related to Dapagliflozin dose in milligrams for healthy subjects and subjects with T2DM. It includes observed values and fitted lines for both groups. The document also contains a phone number and a small numerical value.*
Image (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 03)
Figure 3: Adjusted Mean Change From Baseline Over Time In Hba1c (%) In A 24-week Placebo- Controlled Trial Of Dapagliflozin Tablets In Combination With Metformin (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 04)
This is a description of a clinical study comparing the effects of placebo + metformin to dapagliflozin tablets 10 mg + metformin on HbA1c levels over time. The graphs show the adjusted mean change from baseline HbA1c values at different study weeks, with a focus on Week 24. The study used a longitudinal repeated measures model and ANCOVA model to analyze the data, including randomized subjects who completed the short-term period with both baseline and Week 24 HbA1c values.*
Image4 (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 05)
The text provides data on patients in a study comparing Dapagliflozin to a placebo over 60 months. The number of patients at risk over time is shown for both groups. Dapagliflozin had 8582 patients, while the placebo had 8578 patients at the start. The data includes the event percentages at different time points during the study.*
Image 5 (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 06)
This text provides data related to the medication "Dapagliflozin" and its effects on patients over time. The data includes the number of patients with events, percentages, and the duration in months. It also shows the number of patients at risk over different time points.*
Dapagliflozin Tabletsrx Only5mgndc 70748-105-0630 Tablets Bottle Label (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 07)
This is a description of Dapagliflozin tablets with a dosage of 5 mg per tablet. The tablets are to be stored at 25°C with excursions permitted between 15°C to 30°C. The medication guide should be dispensed to each patient. The manufacturer is Lupin Pharmaceuticals, Inc. from Naples, FL, and the product is manufactured in India. For more information, visit www.lupin.com/dapaglifiozintab-mg.pdf.*
Dapagliflozin Tabletsrx Only10 mgndc 70748-106-0630 Tablets Bottle Label (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 08)
The text provides information about a medication called Dapagliflozin in tablet form, with each tablet containing 10 mg of dapagliflozin. It includes storage instructions, dosage details, and a reference for the Medication Guide available online. The medication is manufactured by Lupin Limited in India. The text also includes a code number for identification purposes and instructions for pharmacists to dispense the medication guide to each patient.*
Image (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 331 1)
Image (8aa1a0ad 3c2c 4534 Ad85 B536748300bf 333 2)
LUPIN and the 4:-: are registered trademarks of Lupin Pharmaceuticals, Inc.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
